Novartis Ag ADR
(NVS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 13,967,000 | 11,563,000 | 7,633,000 | 3,609,000 | 11,939,000 |
| Depreciation Amortization | 5,275,000 | 3,739,000 | N/A | 1,195,000 | 6,114,000 |
| Income taxes - deferred | 2,385,000 | 1,571,000 | N/A | 798,000 | 1,701,000 |
| Accounts receivable | -1,124,000 | -1,030,000 | -1,210,000 | -1,043,000 | -931,000 |
| Accounts payable and accrued liabilities | -273,000 | -375,000 | -315,000 | -172,000 | -105,000 |
| Other Working Capital | -1,577,000 | 10,000 | -1,326,000 | -1,768,000 | -706,000 |
| Other Operating Activity | 491,000 | 1,402,000 | 5,527,000 | 1,026,000 | -393,000 |
| Operating Cash Flow | $19,144,000 | $16,880,000 | $10,309,000 | $3,645,000 | $17,619,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 1,781,000 | 1,770,000 | 1,808,000 | 1,814,000 | -711,000 |
| PPE Investments | -1,535,000 | -927,000 | -574,000 | -244,000 | -1,280,000 |
| Net Acquisitions | -235,000 | -214,000 | -142,000 | -7,000 | -3,911,000 |
| Purchase Of Investment | -116,000 | -63,000 | -46,000 | -18,000 | -193,000 |
| Sale Of Investment | 209,000 | 185,000 | 45,000 | 25,000 | 957,000 |
| Purchase Sale Intangibles | -2,188,000 | -1,892,000 | -1,467,000 | -1,240,000 | -2,368,000 |
| Other Investing Activity | -4,981,000 | -3,524,000 | -3,004,000 | -1,240,000 | -2,375,000 |
| Investing Cash Flow | $-4,877,000 | $-2,773,000 | $-1,913,000 | $330,000 | $-7,513,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 5,000 | 842,000 | 1,406,000 | 556,000 | 958,000 |
| Debt Issued | 6,098,000 | 135,000 | N/A | N/A | 6,143,000 |
| Debt Repayment | N/A | -1,622,000 | N/A | N/A | -289,000 |
| Common Stock Issued | 27,000 | 23,000 | 21,000 | 1,000 | 30,000 |
| Common Stock Repurchased | -9,212,000 | -7,732,000 | -5,430,000 | -2,716,000 | -8,331,000 |
| Dividend Paid | -7,818,000 | -7,818,000 | -7,818,000 | -5,333,000 | -7,624,000 |
| Other Financing Activity | -3,967,000 | -378,000 | -1,940,000 | -1,056,000 | -2,629,000 |
| Financing Cash Flow | $-14,867,000 | $-16,550,000 | $-13,761,000 | $-8,548,000 | $-11,742,000 |
| Exchange Rate Effect | 576,000 | 540,000 | 562,000 | 180,000 | -298,000 |
| Beginning Cash Position | 11,459,000 | 11,459,000 | 11,459,000 | 11,459,000 | 13,393,000 |
| End Cash Position | 11,435,000 | 9,556,000 | 6,656,000 | 7,066,000 | 11,459,000 |
| Net Cash Flow | $-24,000 | $-1,903,000 | $-4,803,000 | $-4,393,000 | $-1,934,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 19,144,000 | 16,880,000 | 10,309,000 | 3,645,000 | 17,619,000 |
| Capital Expenditure | -1,548,000 | -939,000 | -585,000 | -254,000 | -1,366,000 |
| Free Cash Flow | 17,596,000 | 15,941,000 | 9,724,000 | 3,391,000 | 16,253,000 |